NAPSRx

The U.S. Food and Drug Administration (FDA) has granted priority review for Novartis’ investigational medicine, LCZ69 to treat heart failure with reduced ejection fraction (HFrEF).

The U.S. Food and Drug Administration (FDA) approved supplemental New Drug Application (sNDA) for Eisai’s BANZEL®(rufinamide) to be used as an adjunctive treatment of seizures in pediatric patients one to four years old with Lennox-Gastaut Syndrome...

Voyager Therapeutics and Genzyme, a Sanofi company, have entered into a  collaborative deal to develop treatments aimed at combatting fatal and debilitating diseases affecting the central nervous system (CNS).

The U.S. Food and Drug Administration has approved Roche’s Lucentis for the treatment of diabetic retinopathy (DR), in people with diabetic macular edema (DME).

Pfizer Inc has announced their plans to acquire Hospira, Inc in a deal worth approximately $17 billion dollars. Hospira is the world’s leading provider in injectable drugs, infusion technologies and biosimilars.

Novartis’ eye care division, Alcon received approval from the U.S. Food and Drug Administration (FDA) for their ophthalmic solution Pazeo 0.7% to treat ocular itching associated with allergic conjunctivitis.

J & J's Imbruvica has been cleared for expanded approval by the U.S. Food and Drug Administration to treat patients with Waldenström’s macroglobulinemia (WM), a rare cancer that originates in the body’s immune system.

Roche’s pharmaceutical division maintained solid sales for the 2014 year as the company revealed a 4% increase in pharmaceutical sales which were primarily driven by medicines in the oncology and immunology segment.

Novartis’ new vaccine Bexsero® has been granted accelerated approval by the U.S. Food and Drug Administartion (FDA) for the prevention of bacterial meningitis B in adolescents and young adults from 10 years through 25 years of age.

The U.S. Food and Drug Administration's (FDA) Anti-infective Drugs Advisory Committee reached a unanimous decision to recommend approval of Astellas’ CRESEMBA® (isavuconazonium) an investigational treatment for mucormycosis (also known as...